ArticleEmerging infectious diseases2024
Mpox Epidemiology and Risk Factors, Nigeria, 2022.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The epidemiological and clinical differences between patients with mpox and patients without mpox among suspected cases during the recent global mpox outbreaks: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- A three-generation mpox cluster in Chongqing, 2024: transmission chain investigation and phylogenetic characterization.Infection · 2026Article
- Mpox in Sierra Leone and the Mano River Union: an epidemic unfolding in real time.BMJ global health · 2026Review
- Clinical presentation, transmissibility, and virulence of mpox clades in Africa: a systematic review (2023-2025) : Exploring clinical presentation, transmissibility, and virulence of mpox based on clades.Tropical diseases, travel medicine and vaccines · 2026Review
- Mpox outbreak preparedness and response capacity in Nigeria's Federal Capital Territory: a mixed-methods study.BMC public health · 2026Article
- Article
- COVID-19 and MPXV: Twindemic Response and Dual Infections in Individuals in a US Metro.Epidemiologia (Basel, Switzerland) · 2025Article
- Pathogenicity and contact transmissibility of clade IIb MPXV in African dormice.Emerging microbes & infections · 2025Article
- Impact of open markets on zoonotic threats and antimicrobial resistance: A One Health concern.One health (Amsterdam, Netherlands) · 2025Review
- Review
- Neonatal mpox in Nigeria: a case of transplacental or postnatal transmission.BMC infectious diseases · 2025Article
- Recurrent Mpox: divergent virulent clades and the urgent need for strategic measures including novel vaccine development to sustain global health security.BMC infectious diseases · 2025Review
- Non-exanthematous mpox and the implications on response measures during outbreaks.The Pan African medical journal · 2025Article
- Mpox in a non-HIV immunosuppressed host: a case report from Nigeria.The Pan African medical journal · 2025Article
- Mpox outbreak in Abia State, Nigeria, 2024: implications for varicella zoster virus coinfection among children.The Pan African medical journal · 2025Article
- Epidemiology, clinical presentation and outcome of human mpox in Rivers State, Nigeria during the 2022-23 outbreak: an observational retrospective study.The Pan African medical journal · 2025Observational
- The Mpox 2024 Outbreak: The Main Challenges.Balkan medical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate epidemiology of and risk factors for laboratory-confirmed mpox during the 2022 outbreak in Nigeria, we enrolled 265 persons with suspected mpox. A total of 163 (61.5%) were confirmed to have mpox; 137 (84.0%) were adults, 112 (68.7%) male, 143 (87.7%) urban/semi-urban dwellers, 12 (7.4%) self-reported gay men, and 3 (1.8%) female sex workers. Significant risk factors for adults were sexual and nonsexual contact with persons who had mpox, as well as risky sexual behavior. For children, risk factors were close contact with an mpox-positive person and prior animal exposure. Odds of being mpox positive were higher for adults with HIV and lower for those co-infected with varicella zoster virus (VZV). No children were HIV-seropositive; odds of being mpox positive were higher for children with VZV infection. Our findings indicate mpox affects primarily adults in Nigeria, partially driven by sexual activity; childhood cases were driven by close contact, animal exposure, and VZV co-infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.